Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)- N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease

Andrew J. Hirsh, Jim Zhang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Ray A. Caldwell, Juan R. Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, Judith A. St George, M. Ross Johnson, Richard C. Boucher

Research output: Contribution to journalArticle

74 Scopus citations

Fingerprint Dive into the research topics of 'Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)- N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease'. Together they form a unique fingerprint.

Medicine & Life Sciences